The company acquires drug candidates that have undergone initial clinical testing and focuses on developing them for commercial use. Currently, Puma Biotechnology is focused on developing PB-272, an oral neratinib, for the treatment of HER2 positive metastatic breast cancer. They also hold global development and commercialization rights to PB272 (neratinib, intravenous) and PB357. Their mission is to enhance cancer care by bringing innovative therapies to patients, particularly those with HER2+ breast cancer.